| Not Yet Recruiting | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event NCT07499128 | National Cancer Institute (NCI) | N/A |
| Not Yet Recruiting | A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies NCT07476378 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Recruiting | Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma NCT06558604 | The Lymphoma Academic Research Organisation | Phase 2 |
| Not Yet Recruiting | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly D NCT06427213 | Henan Cancer Hospital | Phase 2 |
| Recruiting | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies NCT06045910 | Cancer Research UK | Phase 1 / Phase 2 |
| Recruiting | A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alteratio NCT06136351 | Ruijin Hospital | Phase 2 |
| Recruiting | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer NCT05659732 | PharmaEngine | Phase 1 |
| Withdrawn | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT05431179 | Oncternal Therapeutics, Inc | Phase 3 |
| Completed | A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma NCT05564052 | Janssen Research & Development, LLC | Phase 2 |
| Active Not Recruiting | Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells NCT04911478 | Adicet Therapeutics | — |
| Unknown | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) M NCT05155215 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers NCT05024045 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL NCT04913103 | Czech Lymphoma Study Group | Phase 2 |
| Completed | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) NCT04849416 | Eli Lilly and Company | Phase 2 |
| Active Not Recruiting | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL NCT04662255 | Loxo Oncology, Inc. | Phase 3 |
| Terminated | A Phase 1 Study of ADI-001 in B Cell Malignancies NCT04735471 | Adicet Therapeutics | Phase 1 |
| Completed | A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysp NCT04036448 | Celgene | — |
| Completed | A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cel NCT03190330 | Johnson & Johnson Private Limited | Phase 4 |
| Completed | A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Partic NCT03647124 | Celgene | — |
| Completed | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma NCT03682796 | Triphase Research and Development III Corp. | Phase 1 |
| Completed | Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL NCT03567876 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Completed | Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated Wi NCT03476655 | Johnson & Johnson Private Limited | — |
| Completed | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell NCT02257242 | Brown University | Phase 1 |
| Completed | Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants NCT03053024 | Xian-Janssen Pharmaceutical Ltd. | — |
| Active Not Recruiting | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL NCT02972840 | Acerta Pharma BV | Phase 3 |
| Withdrawn | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ib NCT02743546 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clin NCT03425591 | Janssen-Cilag Ltd. | — |
| Completed | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) NCT02669017 | ADC Therapeutics S.A. | Phase 1 |
| Terminated | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diff NCT02413489 | Janssen Research & Development, LLC | Phase 2 |
| Terminated | Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) NCT02455297 | Bayer | Phase 2 |
| Terminated | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies NCT02454270 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Completed | Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL NCT02419560 | Craig Portell, MD | Phase 1 |
| Completed | A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplant NCT02278796 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Completed | Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment NCT02341781 | Celgene | — |
| Completed | Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Ma NCT02169180 | Janssen Pharmaceutical K.K. | Phase 2 |
| Completed | A Safety Study of SGN-CD19A for B-Cell Lymphoma NCT01786135 | Seagen Inc. | Phase 1 |
| Completed | INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Tem NCT01367457 | Pfizer | — |
| Completed | A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymp NCT01117142 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Unknown | Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) NCT01221103 | Southern Europe New Drug Organization | Phase 1 / Phase 2 |
| Completed | Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL NCT00490529 | Ronald Levy | Phase 2 |
| Completed | Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma NCT00992134 | St. Bortolo Hospital | Phase 2 |
| Completed | A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Re NCT00875667 | Celgene | Phase 2 |
| Completed | A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle C NCT00861510 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Terminated | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) NCT00871546 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Ve NCT00702052 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC NCT00700258 | Pfizer | — |
| Completed | An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphom NCT00420056 | Pfizer | Phase 1 |
| Completed | EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma NCT00114738 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma NCT00261612 | Medical University of Vienna | Phase 2 |
| Unknown | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL NCT00209222 | European Mantle Cell Lymphoma Network | Phase 3 |
| Unknown | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MC NCT00209209 | European Mantle Cell Lymphoma Network | Phase 3 |
| Terminated | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies NCT00514722 | University of California, San Francisco | N/A |
| Completed | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell NCT00038623 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma NCT00992992 | GlaxoSmithKline | Phase 2 |
| Completed | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS NCT00025662 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma NCT00005780 | National Cancer Institute (NCI) | Phase 2 |
| Approved For Marketing | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer NCT05172700 | Loxo Oncology, Inc. | — |